CROI 2017 Program and Information

Program and Agenda

Poster P-G3 PHARMACOKINETICS AND PHARMACOGENETICS: NEW AND EXISTING DRUGS AND FORMULATIONS Poster Hall - 4 EF 415 PHARMACOKINETICS ANALYSIS OF VRC01, A BROADLY NEUTRALIZING HIV-1MONOCLONAL ANTIBODY Yunda Huang 1 , Lily Zhang 1 , Nicole Grunenberg 1 , Robert Bailor 2 , Abby Isaacs 1 , Julie Ledgerwood 3 , Kelly Seaton 4 , Kenneth Mayer 5 , Larry Corey 1 , Peter Gilbert 1 1 Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA, 2 NIAID, Gaithersburg, MD, USA, 3 NIAID, Bethesda, MD, USA, 4 Duke Human Vaccine Inst, Durham, NC, USA, 5 The Fenway Inst, Boston, MA, USA Rana Abutaima 1 , Marta Boffito 2 , Andrea Calcagno 3 , Jessica Cusato 3 , Antonio D’Avolio 3 , Laura Else 1 , Chris Higgs 2 , Saye Khoo 1 , Marco Siccardi 1 , Andrew Owen 1 1 Univ of Liverpool, Liverpool, UK, 2 St. Stephen’s AIDS Trust, Chelsea and Westminster Hosp, London, UK, 3 Univ of Turin, Turin, Italy 417 EFFECT OF CYP3A5 GENOTYPE ON THE PK OFMARAVIROC AND METABOLITES INHEALTHY SUBJECTS Manoli Vourvahis 1 , Sunil Nepal 2 , Annie Fang 1 , Gwendolyn Fate 3 , Linda S. Wood 3 , Jean-Claude Marshall 3 , Andrew Clark 4 , Jayvant Heera 3 1 Pfizer, New York, NY, USA, 2 Pfizer, Biostatistics, Collville, PA, USA, 3 Pfizer, Groton, CT, USA, 4 ViiV Hlthcare, London, UK 418 ABCG2 RS2231142 INFLUENCES TFV CONCENTRATIONS IN PLASMA AND URINE Margherita Bracchi 1 , Megan Neary 2 , Nicole Pagani 1 , Laura Else 2 , Saye Khoo 2 , Zaheer Abbas 1 , David Hawkins 1 , Graeme Moyle 1 , Andrew Owen 2 , Marta Boffito 3 1 Chelsea and Westminster Hosp, London, UK, 2 Univ of Liverpool, Liverpool, UK, 3 Chelsea and Westminster NHS Fndn Trust, London, UK 419 TFV-DP IN DRIED BLOOD SPOTS (DBS) FOLLOWING DIRECTLY OBSERVED THERAPY: DOT-DBS STUDY Peter Anderson 1 , Albert Y. Liu 2 , Jose Castillo-Mancilla 1 , Sharon Seifert 1 , Cricket McHugh 1 , Theresa Wagner 2 , Susan Buchbinder 2 , Lane Bushman 1 , Jennifer J. Kiser 1 , Samantha MaWhinney 1 1 Univ of Colorado Denver, Aurora, CO, USA, 2 San Francisco Dept of Pub Hlth, San Francisco, CA, USA 420 INVITRO AND INVIVO EVALUATION OF BIODEGRADABLE IMPLANT CONTAINING TAF FOR HIV PREP 416 EFFECT OF CYP3A4*22 ON ORAL RILPIVIRINE PLASMA CONCENTRATIONS Phillip G. Durham 1 , Greg Gatto 1 , Leah Johnson 1 , Mark A. Marzinke 2 , Stephanie Swarner 1 , Ginger Rothrock 1 , Tejal Desai 3 , Ian McGowan 4 , Ida Washington 5 , Ariane van der Straten 6 1 RTI Intl, Durham, NC, USA, 2 The Johns Hopkins Univ, Baltimore, MD, USA, 3 Univ of California San Francisco, San Francisco, CA, USA, 4 Univ of Pittsburgh, Pittsburgh, PA, 5 Magee-Womens Rsr Inst, Pittsburgh, PA, USA, 6 RTI Intl, San Francisco, CA, USA 2:30 PM - 4:00 PM

Poster Sessions • Tuesday

CROI 2017 85